A recent article evaluated the concordance rate between tumor and plasma genotyping for detecting actionable genomic alterations to guide targeted therapy. These results support the utility of liquid biopsy for enrolling patients into genomically guided trials, especially in scenarios in which tissue is unavailable or biopsy is not feasible.
Game-Set-MATCH: Liquid Biopsy Advances to the Next Round
Russo, Alessandro;
2025-01-01
Abstract
A recent article evaluated the concordance rate between tumor and plasma genotyping for detecting actionable genomic alterations to guide targeted therapy. These results support the utility of liquid biopsy for enrolling patients into genomically guided trials, especially in scenarios in which tissue is unavailable or biopsy is not feasible.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
